Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Abstract Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS), which worsen patients’ health and increase healthcare spending. The aim of this study was to assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Giovanna Elisiana Carpagnano, Emanuela Resta, Massimiliano Povero, Corrado Pelaia, Mariella D’Amato, Nunzio Crimi, Nicola Scichilone, Giulia Scioscia, Onofrio Resta, Cecilia Calabrese, Girolamo Pelaia, Maria Pia Foschino Barbaro
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/d722a816d07e45d5b82ef3965833a969
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/d722a816d07e45d5b82ef3965833a969

Similar Items